Stevanato Group S.p.A. Engages Investors on Drug Delivery Solutions at Upcoming Conference

### Stevanato Group: A Leader in Drug Delivery Solutions Engages with Investors

Stevanato Group S.p.A., a key player in the global pharmaceutical, biotechnology, and life sciences sectors, prepares for its participation in the upcoming CJS Securities 25th Annual "New Ideas for the New Year" Investor Conference on January 14, 2025. This event showcases the company’s commitment to transparent communication with investors and provides an opportunity to highlight its innovative contributions to drug containment and delivery solutions. The live webcast, available through the company’s "Investors" section on its website, will allow stakeholders to gain insights into Stevanato's operational strategies and growth prospects.

Founded in 1949, Stevanato Group has built a robust reputation for its end-to-end portfolio that addresses the entire drug life cycle—from development through clinical trials to commercial distribution. The company's success is rooted in its strong emphasis on scientific research, technical innovation, and engineering excellence. These core competencies enable Stevanato to remain agile and responsive to the evolving needs of its clientele, ensuring that it continues to deliver value-added services that enhance drug delivery systems across the industry.

As Stevanato Group prepares for the investor conference, it underscores its dedication to addressing the challenges faced by its partners in the pharmaceutical and life sciences landscapes. The event serves not only as a platform for sharing insights but also as a means to strengthen relationships within the investment community. With an ongoing focus on enhancing its capabilities, Stevanato Group positions itself as a pivotal contributor to advancements in drug containment and delivery, ultimately driving progress in healthcare solutions.

In addition to the investor conference, Stevanato Group continues to emphasize its commitment to innovation in the pharmaceutical sector. The company’s integrated solutions are designed to streamline drug development processes, thereby improving efficiency and safety for both manufacturers and end-users. This forward-thinking approach cements Stevanato’s status as a trusted partner in the industry.

For more information about Stevanato Group's offerings and initiatives, stakeholders can visit their website at www.stevanatogroup.com. The company’s proactive engagement with investors reflects its ongoing mission to enhance the pharmaceutical landscape through innovative drug delivery solutions.